UAB MEDICINE

Remdesivir Emergency Use Authorization (EUA) Prioritization for UAB
Updated 1 June 2020

Before considering EUA remdesivir, first page 6157 to try to enroll the patient in a clinical trial (such as ACTT, which includes remdesivir as treatment)

If not eligible for a clinical trial, then to receive EUA remdesivir patient must have SARS-CoV-2 confirmed by lab result within last 72 hours and **cannot** have any of these exclusion criteria:

1. ALT more than 5x upper limit of normal
2. eGFR less than 15 or on renal replacement therapy (HD/CRRT)
3. No radiographic infiltrates on CXR or CT
4. Room air oxygen saturation >94%
5. Cardiac arrest requiring CPR (pre-hospital or in-hospital) without known full neurological recovery
6. Current use of more than 1 vasopressor to maintain blood pressure

---

Patient priority order for using our limited supply of EUA remdesivir (page 6157 to obtain):

1. Intubated within the last 72 hours
2. Not intubated, on supplemental oxygen, PaO2/FiO2 ratio <300 on ABG
3. Intubated between 3-7 days ago

Give all available remdesivir courses to all qualifying patients in priority order.

If there are more patients than drug within priority group 1-3, use lottery to select remdesivir recipients within each priority group.

Treatment course is 5 days for non-intubated patients and 10 days for patients who are intubated at any point during remdesivir therapy. Once a treatment course is completed, do not restart.

If a patient receives EUA remdesivir, they should be provided with this fact sheet prior to administration.

These prioritization document eligibility criteria are based on our current limited supply of EUA remdesivir and are subject to change based on drug availability.

Email Nathan Erdmann (nberdmann@uabmc.edu) or Aadia Rana (airana@uabmc.edu) with questions.